Knowledge of the biochemistry of Plasmodium is emerging as a new field. Previous studies showed that the parasite apparently requires electron transfer for energy, and techniques to study such energy mechanisms are available. 
The advancing new field of the biochemistry of Plasmodium may facilitate the achievement of new antimalarial drugs. P. berghei apparently has a glycolysis mechanism. Fulton (4, 5) . The extent of clumping and utilization of oxygen may be used as assays in support of studies on the bioenergetics of the parasite.
The actual steps of electron transfer for P. berghei are largely unknown. Scheme I, as based on The search for the presence of coenzyme Qn in species of Plasmodium was successful, and mass spectral data and reversed-phase chromatographic results of Rietz et al. (6) showed the presence of coenzyme Qs in P. lophurae. Vitamin (10) and Rudzinska and Trager (11) and the dependence of the parasite upon a gas phase containing a given concentration of oxygen are known; Anfinsen et al. (12) . Drugs General Procedure for 7-Alkylmercapto-6-hydroxy-5,8-quinolinequinones. Seven new 7-alkylmercapto-6-hydroxy-5,8-quinolinequinones were synthesized by treating 6-hydroxy-5,8-quinolinequinoine (16) in ethanol with the appropriate alkyl mercaptan by a modification of the procedure described by Porter et al. (14) . Generally, a solution of starting quinone was refluxed while the alkyl mercaptan in hexane was added. In some reactions, a small amount of sulfuric acid was added. The resulting solutions were refluxed for 4-20 hr.
and then cooled to room temperature. The solvents were removed by distillation in vacuo at room temperature. The resulting purple solid materials were redissolved in chloroform, and the solution was washed thoroughly with water. The chloroform was then removed, and the solid materials were washed with hexane. Finally, the products were recrystallized from chloroform-95% ethanol and/or 95% ethanol. When the desired product was noncrystalline, washing the crude product with both water and hexane became an essential step for the purification. 
RESULTS

Organic Syntheses
The synthesis of the new 7-alkylmercapto-6-hydroxy-5,8-quinolinequinones was accomplished by treating 6-hydroxy-5,8-quinolinequinone in ethanol with the appropriate alkyl mercal)tan as depicted in Scheme II. n-Pentadecyl, n-heptadecyl, n-nonadecyl, and n-docosyl mercal)tans were chosen, because they provided side chain lengths near the optimal length for maximal in vivo activity found ill the series of 7-n- w-Cyclohexylhexyl, oleyl, and phytyl mercaptans provided branched, unsaturated, and isoprenoid side chains. The yields of products were increased by raising the reaction temperature and by adding a small amount of sulfuric acid. However, for reactions involving unsaturated alkyl mercaptans, the addition of sulfuric acid was omitted. Each of the 7-alkylmercapto-6-hydroxy-5,8-quinolinequinones, except 7-phytylmercapto-6-hydroxy-5,8-quinolinequinone, is a dark-purple crystalline compound with a relatively sharp melting point (Table 1) .
Similarly, 6-n-dodecylmercapto-7-methoxy-5,8-quinolinequinone was prepared by treating 7-methoxy-5,8-quinolinequinone in MeOH-Et20 with n-dodecyl mercaptan. Recrystallization and column chromatography of the crude product gave the pure product.
The alkyl mercaptans were prepared from the corresponding acids, alcohols, or bromides. The appropriate acids were reduced with lithium aluminum hydride, and the alkyl bromides were obtained by treating the corresponding alcohols with phosphorus tribromide. The alkyl bromides were allowed to react with thiourea, and the thiouronium salts were hydrolyzed with sodium hydroxide to give the desired mercaptans.
Procedures and data on curative and prophylactic antimalarial activities Representative compounds were tested for antimalarial activity against Plasmodium berghei (blood-induced) in mice (15) (Table 1) , and for prophylactic activity against P. gallinaceum (sporozoite-induced) in chicks (13) (Table 2) . Quinones 1, 2, 4, and 5 were tested against P. berghei. The data in Table 1 show that the heptadecylmercapto derivative (quinone 2) was active at 80 mg/kg, and the pentadecylmercapto derivative was active at 160 mg/kg and cured 2/5 mice at 640 mg/kg. For comparison, the previously published data of quinones 8, 9, 10, and 11 (14) f The compound was declared "active" at this dose level by the standard of 100% increase in survival time.
g The synthesis and assay data for this compound have been published previously (14) . h -Mass spectrum of this compound indicated trace impurities.
Effective Antimalarial Quinones 955 structure between the octadecylmercapto and docosylmercapto derivatives is biologically profound and presumably correlates with precise requirements of the enzyme sites for the functionality and/or biosynthesis of coenzyme Q8 in the parasite.
For the sporozoite-induced and prophylactic chick tests, the data are in Table 2 . For comparison, the previously synthesized tetradecylmercapto, hexadecylmercapto, and octadecylmercapto derivatives are included in Table 2 , because assay data are now available. The prophylactic antimalarial activity in this assay is not only effective but prominent in this group of 7-alkylmercapto-6-hydroxy-5,8-quinolinequinones. The heptadecylmercapto derivative (quinone 2) cured 5/5 mice at only 10 mg/kg and is presumably active at even lower dose levels. The absence of toxicity at 320 mg/ kg demonstrates an exceptional margin of safety. The octadecylmercapto derivative showed only marginal activity at 100 mg/kg, and the nonadecylmercapto derivative was active but less active than the heptadecylmercapto derivative. Consequently, increasing the chain length beyond seventeen carbon atoms reduced activity. Shortening the chain length to the hexadecylmercapto derivative resulted in 5/5 cures at 120 mg/kg, which was the lowest dosage tested. The tetradecylmercapto derivative showed diminished activity in comparison with the heptadecylmercapto derivative. It appears that maximal activity of these 7-alkylmercapto-6-hydroxy-5,8-quinolinequinone resides in those compounds having 15, 16, and 17 carbon atoms in their saturated straight alkyl groups. Quinone 6, possessing one double bond in the 7-alkylmercapto group, symbolizes the unexplored potentiality of even better activity, since unsaturation is natural in the isoprenoid side chain of coenzyme Q8. The octadecylmercapto analog showed 1/5 cures at 40 mg/kg in comparison with the oleylmercapto analog with 1 unit of unsaturation, which showed 4/5 cures at 15 mg/kg; apparently, unsaturation in this alkyl side chain enhances prophylactic activity.
7-n-Octadecylmercapto -6 -acetoxy -5,8 -quinolinequinone (quinone 12) cured 2/5 mice at 80 mg/kg, 4/5 mice at 160 mg/kg, and 5/5 mice at 320 mg/kg in the prophylactic chick assay. No toxicity was evident at 320 mg/kg for the 6-acetoxy TABLE 2. Antimalarial activity of certain alkylmercaptoquinones in the sporozoite-induced chick test (13) e This compound has been previously synthesized (14) . d The compound was declared "active" by the standard of 100% increase in survival time.
Ca H, N analyses for compound 12 were within 0.40% of calculated values. quinone, but the corresponding 6-hydroxy quinone showed 2/5 toxic deaths at 320 mg/kg. 3 -n -Dodecylmercapto -2 -hydroxy -1,4 -naphthoquinone (quinone 13) was inactive in the chick assay. The pyrido moiety of the quinolinequinone system is apparently important for the inhibitory role in these quinones, possibly because of its influence on the oxidation-reduction potential and/or binding at receptor sites.
Initial tests in two rhesus monkeys showed suppression of P. cynomolgi when the 7-octadecylmercapto derivative was intravenously administered at a dosage of 3.16 mg/kg per day for 7 consecutive days. When this compound was given intraperitoneally at the same dose level (3.16 mg/kg per day), one of two monkeys died of drug toxicity; the monkey that survived the drug toxicity showed no beneficial effects of the compound given. Intravenous administration at 10 mg/kg per day produced toxic deaths in two of three monkeys; intraperitoneal administration at 10 mg/kg per day produced peritonitis and/or drug toxicity so severe that 4/4 monkeys died by day 15 . This compound was completely ineffective by the oral route of administration at 31.6 mg/kg and 10 mg/kg. The compound was given at each dosage level to two monkeys for 7 consecutive days. No toxicity was seen.
DISCUSSION
The structural comparison (Scheme III) of the heptadecylmercapto derivative, 2, and coenzyme Q8 shows the potentially competitive relationship for inhibition of functionality in the electron transfer mechanism of the parasite. The comparison of the heptadecylmercapto derivative with the three precursors 14, 15, and 16, which are quinones in the projected biosynthesis (19) of coenzyme Q% by the parasite, shows the potentiality of additional sites of inhibition for antimalarial activity.
Although antimetabolic activity or inhibition of coenzyme Q enzymes has been demonstrated (14) for these particular quinones, the biochemical basis of the antimalarial activity, in vivo, can be the resultant of single or multiple inhibition(s) of the functionality and/or the biosynthesis of coenzyme Q8 as well as other metabolic reactions.
The assays of these quinones against P. berghei in mice and P. gallinaceum in chicks is only a screening system, albeit a very efficient one. As such, the test compounds are administered only once. Consequently, the effectiveness of the heptadecylmercapto derivative in the prophylactic chick test is indeed impressive. It may be assumed on the basis of conventional chemotherapy that multiple dosage, in vivo, could yield data even more impressive than that presently available on the single-dosage schedule.
